A new vaccine is set to undergo testing based on the use of non-pathogenic viruses with anti-cancer activity, which will be administered to patients.
Russia will begin Phase 1 clinical trials of an anti-cancer vaccine by the end of 2024 and early 2025.
This announcement was made by Andrey Kaprin, the chief oncologist of the Russian Federation’s Ministry of Health and the General Director of the National X-ray Medical Research Center.
Vaccination. (Photo: AFP/TTXVN).
According to a correspondent in Russia, this vaccine, as explained by Kaprin, utilizes non-pathogenic viruses with anti-cancer properties that will be introduced into the patients’ bodies.
Animal testing has shown that this vaccine is non-toxic and demonstrates high efficacy.
The results of preclinical trials have allowed for the transition to clinical trials on humans.
The vaccine application has been submitted to the Ministry of Health to seek approval for recruiting a group of volunteers for human trials. According to Kaprin, these volunteers must not have undergone chemotherapy.
Kaprin also mentioned that research on mRNA vaccines in cancer treatment continues. The mRNA technology vaccine will be administered to patients in a “super precise” manner, aiming to create a “tumor passport,” referred to as a new antigen profile.
Alexander Gintsburg, Director of the Gamaleya Research Center for Epidemiology and Microbiology, stated that patients with melanoma and lung cancer will be the first to trial the vaccine.
Earlier in July, Kaprin reported that the mortality rate for cancer patients in Russia has decreased in the first year after diagnosis. This figure has dropped by over 5% in the past eight years.
According to Kaprin, the mortality rate was 23.6% in 2015 and has decreased to 18.3% in 2023. Compared to 2022, the cancer mortality rate in the first year has fallen by 4.7%.
At the same time, cancer detection is improving: in 2023, cancer was diagnosed in 74,587 individuals, an increase of 8% compared to 2021.
